Biolux secures CHF 4 million seed funding led by redalpine to enhance its innovative light-accelerated orthodontics solutions in a rapidly growing market.

Target Information

Biolux, part of RAC VII, is dedicated to revolutionizing orthodontic treatments through its innovative approach to light-accelerated orthodontics. The company aims to alleviate the common challenges associated with traditional orthodontic methods, which often involve lengthy, costly, and uncomfortable procedures for patients. With the orthodontics market projected to grow to $21 billion by 2030, Biolux's flagship product, Orthopulse, utilizes near-infrared light therapy to accelerate tooth movement, thereby reducing treatment periods and enhancing patient comfort significantly.

Industry Overview in Switzerland

Switzerland is renowned for its robust healthcare system, which stands as one of the most advanced globally. The orthodontics sector is experiencing notable growth, fueled by increasing demand for effective and less invasive treatments. As technological advancements continue, the industry is witnessing a shift towards more innovative solutions like Biolux’s Orthopulse. This evolution emphasizes the integration of cutting-edge technology to improve patient outcomes.

Additionally, the Swiss healthcare and dental markets are characterized by their high standards of patient care, which sparks a drive for continuous improvement among practitioners. Dental he